Theravance to Report First Quarter 2015 Financial Results on May 6, 2015
(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/29/15 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will report financial results for the first quarter ended March 31, 2015 after market close on Wednesday, May 6, 2015. Theravance management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update.
To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at and will be archived there for 30 days. A telephone replay of the call will be available by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers and entering the confirmation code 24756499.
Theravance, Inc. is focused on maximizing the potential value of the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, with the intention of providing capital returns to stockholders. Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement with GSK, Theravance is eligible to receive the associated royalty revenues from RELVAR®/BREO® ELLIPTA® (fluticasone furoate/vilanterol, "FF/VI"), ANORO® ELLIPTA® (umeclidinium bromide/vilanterol, "UMEC/VI") and if approved and commercialized, VI monotherapy. Theravance is also entitled to a 15 percent economic interest in any future payments made by GSK under agreements entered into prior to the spin-off of Theravance Biopharma, and since assigned to Theravance Respiratory Company, LLC, relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under these agreements with GSK (other than RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and VI monotherapy). For more information, please visit Theravance''s website at .
RELVAR®, BREO®, ANORO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.
(THRX-F)
Eric d''Esparbes
Senior Vice President and Chief Financial Officer
650-238-9640
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.04.2015 - 14:05 Uhr
Sprache: Deutsch
News-ID 1355152
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SOUTH SAN FRANCISCO, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Theravance to Report First Quarter 2015 Financial Results on May 6, 2015
"
steht unter der journalistisch-redaktionellen Verantwortung von
Theravance, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
